Protagonist Therapeutics, Inc.
(NASDAQ : PTGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.34%171.531.3%$493.60m
BIIBBiogen Inc.
-1.18%226.411.3%$458.58m
CELGCelgene Corporation
-0.23%95.411.3%$443.43m
GILDGilead Sciences, Inc.
-0.57%66.790.9%$425.86m
ILMNIllumina, Inc.
1.54%313.743.5%$309.89m
REGNRegeneron Pharmaceuticals, Inc.
-0.72%312.992.6%$291.45m
AAgilent Technologies, Inc.
1.74%68.881.6%$213.28m
VRTXVertex Pharmaceuticals Incorporated
-0.61%171.961.9%$178.78m
EXASExact Sciences Corporation
3.03%96.8525.3%$167.97m
ALXNAlexion Pharmaceuticals, Inc.
1.76%127.542.0%$150.24m
BMRNBioMarin Pharmaceutical Inc.
2.10%88.804.3%$118.51m
INCYIncyte Corporation
1.24%81.502.5%$108.29m
SRPTSarepta Therapeutics, Inc.
2.18%120.8314.7%$106.92m
ALNYAlnylam Pharmaceuticals, Inc
1.89%69.199.2%$97.27m
IONSIonis Pharmaceuticals, Inc.
-3.90%64.528.2%$93.37m

Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.